US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.06

+0.18000.48%

Volume:114.36K

Turnover:4.36M

Market Cap:256.91M

PE:- -

High:38.28

Open:38.22

Low:38.01

Close:37.88

52wk High:41.49

52wk Low:22.33

Shares:6.75M

Float Shares:6.75M

Volume Ratio:0.62

T/O Rate:1.69%

Dividend:0.28

Dividend Rate:0.74%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cellectis pivots to in vivo gene editing and exits key CAR-T programs

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Vertex Minerals Revises Timeline for Proposed Securities Issue

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

Scholar Rock announces FDA approval of isembyld

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

IntegraGen receives rival takeover bids amid court‑ordered restructuring

Pharming wins FDA nod to extend Joenja use to younger APDS children

Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis

Moderately bullish activity in Moderna with shares up 8.03%

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating

MT Newswires Live

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/IDNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":38.06,"timestamp":1789156800000,"preClose":37.88,"halted":0,"volume":114363,"delay":0,"changeRate":0.004751847940865884,"floatShares":6750000,"shares":6750000,"eps":0,"marketStatus":"Pre-Mkt","change":0.18,"latestTime":"09-14 04:45:04 EDT","open":38.22,"high":38.28,"low":38.005,"amount":4356036.121553999,"amplitude":0.00726,"askPrice":43.56,"askSize":100,"bidPrice":34.56,"bidSize":3,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":38.06,"sharesOutstanding":5100000,"nav":37.991633,"aum":258343104.4,"dividendRate":0.007399,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.06,"preClose":38.06,"latestTime":"19:30 EDT","volume":20,"amount":761.1742,"timestamp":1789169407146,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6184424703621776,"impliedVol":0.1978,"impliedVolPercentile":0.516},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6184424703621776,"shares":6750000,"dividePrice":0.2816,"high":38.28,"amplitude":0.00726,"preClose":37.88,"low":38.005,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":38.06,"committee":-0.941748,"eps":0,"divideRate":0.007399,"volume":114363,"delay":0,"ttmEps":0,"open":38.22,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":40.29,"twentyDayClose":35.24,"sixtyDayClose":29.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667376655","title":"Cellectis pivots to in vivo gene editing and exits key CAR-T programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2667376655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667376655?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:15","pubTimestamp":1789370144,"startTime":"0","endTime":"0","summary":"Cellectis SA ( ($FR:ALCLS) ) has provided an announcement. Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cellectis-pivots-to-in-vivo-gene-editing-and-exits-key-car-t-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","WDNA","HELX","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653981","title":"Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653981","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653981?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:40","pubTimestamp":1789368000,"startTime":"0","endTime":"0","summary":"Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by con","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360712/0/en/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","BK4156","BK4139","SYNB","HELX","CLLS","WDNA","GNMX","IDNA","NC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635488","title":"Vertex Minerals Revises Timeline for Proposed Securities Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635488?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:40","pubTimestamp":1789342824,"startTime":"0","endTime":"0","summary":"Vertex Minerals Ltd. ( ($AU:VTX) ) has provided an update. Vertex Minerals Ltd. has updated its proposed securities placement timetable, revising t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-revises-timeline-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-revises-timeline-for-proposed-securities-issue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0058720904.USD","LU0109394709.USD","SG9999001176.USD","MTX","LU0234570918.USD","VERX","LU1559883803.SGD","LU1674673691.USD","BBH","LU0566484027.USD","PBE","LU2462157665.USD","LU1585245621.USD","LU1815336091.USD","TBXU","SG9999001176.SGD","LU0061475181.USD","IE00BJJMRZ35.SGD","BK4585","IBBQ","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2089984988.USD","BK4532","SGXZ57979304.SGD","LU0757428866.USD","LU1674673428.USD","LU0320765992.SGD","LU0079474960.USD","IE0009355771.USD","LU0432979614.USD","LU1430594728.SGD","LU2468319806.SGD","IDNA","BIB","IE00BJT1NW94.SGD","BK4109","LU2362541273.HKD","IE00B19Z9P08.USD","IBB","VRTX","BK4533","LU0256863811.USD","GNMX","BK4588","IE00B2B36J28.USD","LU1093756325.SGD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4179","MRNX","GNMX","MEDI","BMED","IBB","NVIB","RSPH","BK4139","GDOC","LFSC","XLVX","PINK","BK4588","BK4585","BBP","FET","IEIH","TECB","IDNA","IYH","MRNY","SYNB","LABU","PSCH","FRTY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668081","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668081?lang=en_us&edition=fundamental","pubTime":"2026-09-14 01:20","pubTimestamp":1789320035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Cooper Co (COO) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","XLV","COO","BK4588","LABU","GB00BDT5M118.USD","BK4585","BBH","IDNA","XBI","HCSG","RVMD","IE0009354923.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1992135472.HKD","BK4198","LU2211815571.USD","PTH","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU0128526141.USD","LU2272731782.SGD","BK4137","IE00BJJMRZ35.SGD","BK4581","CANC","LU2272731600.USD","LU1992135399.USD","BK4139","IE00B4R5TH58.HKD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XLVX","MRNY","PSCH","IYH","THNR","BMED","FRTY","BK4588","IDNA","IEIH","SYNB","GDOC","RSPH","IBRN","TECB","LFSC","GNMX","BK4585","BK4139","NVIB","LABU","PINK","SRRK","MEDI","TBXU","BBP","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574302","title":"Moderna Inc. Stock Rallies 5.4%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574302?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:33","pubTimestamp":1789158780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. advanced 5.4% to $143.97 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.0% to 26,333.04 and the Dow Jones Industrial Average rising 1.0% to 52,573.29.This was the stock's second consecutive day of gains.Moderna Inc. closed 18.5% short of its 52-week high of $176.66, which the company achieved on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.3% to $265.58, Pfizer Inc. rose 0.3% to $27.72, and Gilead Sciences Inc. fell 0.75% to $143.72.Trading volume totaled 15.3 million, compared to the 50-day average of 17.4 million.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","TMED","BK4568","LU0965509010.AUD","LGHT","IE00BKVL7J92.USD","BK4548","LU0965508806.USD","LU1674673428.USD","BIB","IDNA","BMED","WDNA","LU1934455277.USD","LU0058720904.USD","IBB","SG9999015986.USD","LU1571399168.USD","SG9999015978.USD","MRNX","MRNA","LU0289739699.SGD","LU1066051498.USD","LU0965509283.SGD","GNOM","IE00BSNM7G36.USD","LU1674673691.USD","BK4534","LU2468319806.SGD","IBBQ","MEDI","TBXU","BK4578","GILD","IE00B3T34201.USD","LU0114720955.EUR","LU0965509101.SGD","LU1057294990.SGD","LU0861579265.USD","LU1585245621.USD","BBH","LU0109394709.USD","SG9999015952.SGD","IE00B19Z3581.USD","LU0889565916.HKD","LU1430594728.SGD","LU2357627491.SGD","BK4588","LU1778281490.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666579410","title":"IntegraGen receives rival takeover bids amid court‑ordered restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2666579410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666579410?lang=en_us&edition=fundamental","pubTime":"2026-09-12 03:02","pubTimestamp":1789153348,"startTime":"0","endTime":"0","summary":"IntegraGen SA ( ($FR:ALINT) ) has provided an update. IntegraGen SA, a French genomics company focused on cancer and rare genetic diseases, provide...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/integragen-receives-rival-takeover-bids-amid-courtordered-restructuring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/integragen-receives-rival-takeover-bids-amid-courtordered-restructuring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","DARP","FWD","GNMX","TARK","IDNA","GNOM","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","BBP","IYH","TBXU","GNMX","IEIH","LFSC","IBB","SYNB","LABU","MRNX","NVIB","MRNY","BK4585","PINK","PSCH","FRTY","BMED","TECB","BK4588","RSPH","GDOC","IDNA","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666575576","title":"Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666575576","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666575576?lang=en_us&edition=fundamental","pubTime":"2026-09-12 01:15","pubTimestamp":1789146928,"startTime":"0","endTime":"0","summary":"• Moderna experienced upward volatility driven by renewed institutional buying and consolidation.\n• Phase 3 trial results for intismeran autogene validated its oncology platform.\n• Latest annual revenue is $1.94B with a net loss of $-2.82B.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262164027-market-movers-mrna-20260911","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","MRNA","BK4551","BK4585","BK4534","GNOM","BK4532","BK4533","MRNY","IDNA","MRNX","BK4568","BK4548","BK4139","BK4588","WDNA","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666576334","title":"Moderately bullish activity in Moderna with shares up 8.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666576334?lang=en_us&edition=fundamental","pubTime":"2026-09-12 01:00","pubTimestamp":1789146015,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares up $10.97, or 8.03%, near $147.59. Options volume roughly in line with average with 139k...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-up-8-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-up-8-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4534","BK4551","BK4588","MRNX","BK4532","WDNA","LGHT","BK4548","BK4501","BK4568","IDNA","BK4585","BK4139","MRNY","GNOM","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666573009","title":"S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2666573009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666573009?lang=en_us&edition=fundamental","pubTime":"2026-09-12 00:00","pubTimestamp":1789142409,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500.SPXTop PerformersPercent ChangeDell Technologies IncDELL.N+11.0%Hewlett Packard Enterprise CompanyHPE.N+9.1%Skyworks Solutions, Inc.SWKS.OQ+8.1%Moderna, Inc.MRNA.OQ+8.1%Flex LtdFLEX.OQ+7.8%Bottom PerformersPercent ChangeSeagate Technology Holdings PLCSTX.OQ-3.6%Baker Hughes CompanyBKR.OQ-3.1%SanDisk CorporationSNDK.OQ-3.1%The Clorox CompanyCLX.N-2.9%Palo Alto Networks, Inc.PANW.OQ-2.6%As of 12:00 p.m., the S&P 500.SPXgained 78.63 points, or 1.04%, to 7,670.33 and had posted 7 new 52-week highs and 6 new lows.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL8N4531EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4550","LU1983260115.SGD","LU2265009873.SGD","SPHQ","PALU","LU1861220033.SGD","LU1989764664.SGD","ITOT","SPYQ","BK4554","IE00BN0W2T93.GBP","LU1670627923.USD","LU0175139822.USD","LU2210149790.SGD","LU2210150020.SGD","SPUS","LU0128525689.USD","LU0823434740.USD","BKR","SPXL","FCUS","SNXX","WCBR","BK4145","IGV","LU0081259029.USD","MRNA","SCHB","CNAV","LU1992135399.USD","LU1823568750.SGD","EGGY","ETFT","IE00B894F039.SGD","IJH","BK4515","VEU","LU2290526834.HKD","SPHD","SPYH","BUG","BK4581","LU0154245756.USD","LU0289739343.SGD","LU2065170008.USD","WCLD","BK4139","HPE","PANW","LU0256331488.USD","RSPU","HPEL","SPYD","SNDK","LU0511384066.AUD","LU2286300806.USD","IE00B19Z8W00.USD","LU1720051108.HKD","IDNA","LU1917777945.USD","LU0251142724.SGD","BK4179","SMAX","LU0321505439.SGD","LU2322448791.USD","BK4598","DRMY","NOBL","SPGP","LU1366192091.USD","LU0006061336.USD","LU2272731865.HKD","JEPI","BK4560",".SPX","BK4141","LU0052756011.USD","LU0057025933.USD","LU2272731782.SGD","LU2244417387.USD","RSPA","BK4566","IEZ","LU0348723411.USD","LU1235294995.USD","LU2106854487.HKD","IE00B19Z9505.USD","LU2322448957.HKD","QQQG","HIBL","LU1169590202.USD","BK4567","IJR","TMSL","LU0048573561.USD","BK4585","BK4504","BK4548","DBSC","LU1989764748.USD","LU2125909916.SGD","LU1261432733.SGD","VV","BK4535","IVE","VOOG","DMAX","FXL","GPIX","MRNX","RULE","LU0070302665.USD","LU1992135472.HKD","LU0208291251.USD","BK4551","OIH","PALD","LU0289961442.SGD","GSLC","BK4605","LU0203345920.USD","SFY","VOO","LU0345770993.USD","LU2023250843.SGD","SPYU","PTF","CLX","CIBR","DISK","LU1923622291.USD","BK4512","LU1974910355.USD","LU2543165471.USD","SH","STXL","LU1267930227.SGD","SNDG","IE00BZ1G4Q59.USD","GNOM","SCHA","SPLV","BMAY","SSO","LU2065171311.SGD","LU2357305700.SGD","LU2065171402.SGD","SCHM","LU0823434583.USD","PSWD","VTI","STXU","LU0082616367.USD","LU0187121727.USD","UPRO","LU1712237335.SGD","BK4097","LU0306806265.USD","LU1084165304.USD","LU1046421795.USD","LU1169589451.USD","XDTE","LU0069063385.USD","BK4533","LU0124676726.USD","LU1623119135.USD","SPY","LU0742534661.SGD","PXJ","LU0823421333.USD","SPXU","VBK","LU1720051017.SGD","BK4018","LU1119994496.HKD","MMAX","VTV","BK4532","LU0496365809.HKD","BK4170","LGHT","BK4543","LU0234570918.USD","CLOD","LU0345770308.USD","SPYV","LU0689626769.HKD","BK4534","LU0225771236.USD","LU2272731600.USD","MRNY","STXX","LU0963586101.USD","MOAT","IE00B19Z3B42.SGD","SPYM","LU1548497426.USD","SPYG","LU1804176565.USD","SCHX","LU1670628061.USD","FLEX","LU2360107168.USD","IE00BN0W2W23.USD","FLEL","LU0306807586.USD","HIBS","LU2098885051.SGD","IE00B7SZLL34.SGD","IE00BMPRXR70.SGD","LU2023250504.SGD","RSPN","ALLW","LU0320765489.SGD","OPTZ","SPAM","LU0225284248.USD","LU2355687059.USD","YSPY","SNDC","XYLD","BK4501","WLDR","LU1153585028.USD","LU0211331839.USD","LU2063271972.USD","QQQA","IVW","LU0985481810.HKD","LU0289960550.SGD","STX","PANG","LU2473716301.USD","XLG","LU0267386448.USD","LU0154245673.USD","SNDQ","IE0002270589.USD","SPMO","IE00B19Z8X17.USD","AIFD","HAKY","IE00B19Z3581.USD","IE00BMPRXN33.USD","IVV","LU0054578231.USD","LU0266013472.USD","LU0203347892.USD","LU0211326755.USD","LU0472753341.HKD","RSP","IE00B19Z9P08.USD","IE00BKVL7J92.USD","LU0719512351.SGD","SG9999001424.SGD","SPDN","ACWI","IE00B19Z9Z06.USD","TSPY","LU0823421416.USD","IE00BN0W2V16.EUR","WDNA","BK4568","DELL","DLLL","IHAK","LU0211326839.USD","LU0321505868.SGD","LU2065169927.USD","LU2095319765.USD","COWG","BK4588","SDS","SWKS","LU0011850046.USD","LU1861215975.USD","LU0310800965.SGD","SPXS","LU0251131958.USD","FSMD","LU1571399168.USD","LU2125909759.SGD","SNDU","LU0976567544.SGD","SPUU","LU1303367103.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529289","title":"Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529289","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529289?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125772,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $112.72, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WDNA","BK4139","BK4501","BK4532","MRNA","GNOM","BK4585","BK4568","IDNA","BK4551","BK4533","BK4534","LGHT","MRNX","BK4548","MRNY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666422435","title":"Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666422435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666422435?lang=en_us&edition=fundamental","pubTime":"2026-09-11 16:20","pubTimestamp":1789114812,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA), Merck & Company (MRK) and Pacific ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-merck-company-mrk-and-pacific-biosciences-pacb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-merck-company-mrk-and-pacific-biosciences-pacb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","LU2491049909.HKD","SG9999002224.SGD","LU1162221912.USD","LU2112291526.USD","LU0289739699.SGD","LU1037948897.HKD","LU2125154935.USD","LU0689626769.HKD","LU0208291251.USD","LU0320765489.SGD","LU1989772840.SGD","FTXH","IHE","PACB","PPH","IE00BLSP4452.SGD","SG9999014575.USD","LU0122379950.USD","LU1093756168.USD","BK4548","LU1983299246.USD","LU2357627491.SGD","LU1066051811.HKD","IE00B4R5TH58.HKD","LU2361044865.SGD","IE0009355771.USD","LU0965509101.SGD","LU0203345920.USD","LU1974910355.USD","LU1201861249.SGD","LU0823416689.USD","IE00BN8TJ469.HKD","IDNA","BK4559","SG9999014559.SGD","LU0980610538.SGD","IE00B1BXHZ80.USD","IE0002141913.USD","BK4501","IE00BBT3K403.USD","LU1941712264.USD","FHLC","SG9999001176.USD","BK4516","LU0130517989.USD","LU1066051225.USD","LU1585245621.USD","LU0124676726.USD","SG9999014567.USD","LU1934455194.USD","LU0006306889.USD","BK4533","LU0265550946.USD","SG9999002232.USD","LU1023059063.AUD","WDNA","LU0868494617.USD","LU1066053197.SGD","LU0098860793.USD","BK4551","LU0238689110.USD","LU0965508806.USD","LU1699723380.USD","LU2361045086.USD","BK4121","IE00BSNM7G36.USD","LU0942090050.USD","IE00BLSP4239.USD","LU2125154778.USD","GDOC","LU0985320562.USD","LU2360032135.SGD","SGXZ57979304.SGD","LU0130102774.USD","BK4550","BK4007","LU1066051498.USD","LU2361044949.HKD","LU1032466523.USD","LU0477156953.USD","LU2125909593.SGD","LU2106854487.HKD","MRNA","LU0203347892.USD","MRK","MRNX","LU1941712348.USD","LU0106261372.USD","LU0965509283.SGD","LU1989771016.USD","LU1057294990.SGD","BK4532","LU1929549753.HKD","IXJ","BK4588","VHT","LU0965509010.AUD","LU2433249047.HKD","LU1035773651.USD","LU0320765646.SGD","LU2468319806.SGD","LU1093756325.SGD","LU2023250504.SGD","LU0058720904.USD","LU2491050154.USD","LU2324357040.USD","LU1069347547.HKD","LU0432979614.USD","LU0648001328.SGD","LU1291159041.SGD","BK4585","LU1917777945.USD","GNOM","IYH","LU1934455277.USD","LU0859254822.USD","SG9999015358.SGD","LU1923622614.USD","LU1934455863.HKD","LU1061106388.HKD","LU1116320737.USD","LU0234572021.USD","LU0211331839.USD","LU2089984988.USD","LU0868494708.USD","SG9999014542.SGD","LU1989772923.USD","JDOC","BK4534","RXL","BMED","LU1116320901.HKD","LU1571399168.USD","LU2491050071.SGD","LU1430594728.SGD","TRUH","PAWZ","LU0070302665.USD","SG9999013999.USD","LU2125909247.SGD","IE00BFTCPJ56.SGD","SG9999001176.SGD","IE00BJJMRZ35.SGD","BK4139","HRTS","IE00B2B36J28.USD","IE000M9KFDE8.USD","LU2461242641.AUD","SG9999001440.SGD","SG9999015341.SGD","LU0266013472.USD","LU1037948541.HKD","LGHT","LU0861579265.USD","LU2023250843.SGD","LU0265550359.USD","BK4568","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666546340","title":"Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2666546340","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666546340?lang=en_us&edition=fundamental","pubTime":"2026-09-11 13:57","pubTimestamp":1789106251,"startTime":"0","endTime":"0","summary":"Vertex Minerals Ltd. ( ($AU:VTX) ) just unveiled an update. Vertex Minerals has amended its previously released updated mineral resource estimate f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-confirms-reward-gold-mine-resource-after-asxdriven-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-confirms-reward-gold-mine-resource-after-asxdriven-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU0417517546.SGD","LU1035775433.USD","LU2456880835.USD","LU2468319806.SGD","LU2362541513.USD","LU1093756325.SGD","LU2462157665.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","BIB","BK4532","BK4567","SGXZ57979304.SGD","LU1778281490.HKD","IE00B19Z9P08.USD","LU1559883803.SGD","BK4588","LU2362541273.HKD","GNMX","VRTX","IBBQ","LU0256863811.USD","LU0058720904.USD","BBH","IBB","IE00B19Z3B42.SGD","LU0109394709.USD","IDNA","IE00B19Z9Z06.USD","IE0002141913.USD","LU1815336091.USD","LU2362540622.SGD","SGDJ","LU2237438978.USD","LU0320765992.SGD","BK4109","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","MTX","PBE","LU2236285917.USD","VERX","BK4533","SG9999001176.SGD","LU2417539215.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666111665","title":"The Race for the Next Big Weight-Loss Drug is On-and China Wants In","url":"https://stock-news.laohu8.com/highlight/detail?id=2666111665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666111665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:00","pubTimestamp":1789084800,"startTime":"0","endTime":"0","summary":"SHANGHAI-Chinese biotech companies, rapidly evolving from manufacturers of low-end generic drugs to serious competitors to American pharma giants, are training their sights on one of the most lucrativ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","NVIB","GDOC","MEDX","BMED","IDNA","XBIX","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516010","title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516010","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516010?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:53","pubTimestamp":1789077203,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of 17,090 common shares worth USD 3.57 millionDirector Lorence H. Kim disclosed sales of 17,090 Revolution Medicines common shares on Sep. 8, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1wDHJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE0009354923.USD","RVMD","CANC","IE00BFTCPJ56.SGD","IDNA","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","PTH","BBH","IE00B4R5TH58.HKD","BK4139","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515515","title":"Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515515","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666515515?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:16","pubTimestamp":1789071415,"startTime":"0","endTime":"0","summary":"Vertex Pharma EVP Jasper van Grunsven files initial beneficial ownership statementVertex Pharmaceuticals EVP Jasper van Grunsven filed an initial Form 3 insider ownership statement dated Sept. 8, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL2ylbPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0002141913.USD","LU0889565916.HKD","LU1585245621.USD","TBXU","GNMX","PBE","LU0823416689.USD","SGXZ57979304.SGD","LU1674673428.USD","IBB","IE00B2B36J28.USD","LU0289739699.SGD","VRTX","LU2237438978.USD","LU1069344957.HKD","IE00B19Z9Z06.USD","IE0002270589.USD","LU2236285917.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU2324357040.USD","LU0079474960.USD","LU0432979614.USD","LU1035775433.USD","LU0058720904.USD","BK4585","LU1430594728.SGD","LU2089984988.USD","LU2456880835.USD","SG9999001176.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4532","BBH","BK4533","IE0009355771.USD","LU1093756168.USD","BIB","LU0061475181.USD","IE00B894F039.SGD","IBBQ","LU2417539215.USD","LU0256863811.USD","LU1674673691.USD","IDNA","LU2362540622.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518829","title":"Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518829","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518829?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:40","pubTimestamp":1789065600,"startTime":"0","endTime":"0","summary":"Revolution Medicines barely had time to celebrate the landmark approval of its pancreatic cancer pill before Wall Street demanded to know what's next.Late last month, regulators approved daraxonrasib ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU1032466523.USD","LU0109394709.USD","LU1670711040.USD","IE00BFTCPJ56.SGD","LU0985481810.HKD","IE00BSNM7G36.USD","PTH","IE0002141913.USD","IE00BFXG1179.USD","LU2360032135.SGD","IDNA","LU1236620750.USD","LU1983299246.USD","LU1236620834.HKD","LU1868837300.USD","IHE","BK4585","LU0432979614.USD","LU0456855351.SGD","LU0096364046.USD","FTXH","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1585245621.USD","LU0321505439.SGD","LU0882574055.USD","LU1868836757.USD","LU2125154935.USD","LU2133065610.SGD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4534","LU1670710588.SGD","LU1571399168.USD","BBH","IE0009354923.USD","LU1093756168.USD","LU0321505868.SGD","BK4581","LU1868836591.USD","BMY","CANC","RVMD","BK4559","LU0237698245.USD","IE0009355771.USD","LU0114720955.EUR","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359288","title":"Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359288?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:29","pubTimestamp":1789054182,"startTime":"0","endTime":"0","summary":"Revolution Medicines  could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional  sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disapp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD","BBH","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","LU0889565916.HKD","CANC","IE00BJJMRZ35.SGD","IDNA","IE0009354923.USD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","LU0109394709.USD","PTH","IE0002141913.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}